ClinicalTrials.gg
Not yet recruitingNCT06500299Updated Jul 15, 2024

Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

A Phase 2 interventional study of HDM1002 100 mg QD and HDM1002 200 mg QD 12weeks in Overweight and Obesity, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-15.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Obesity by Huadong Medicine Co., Ltd. — 10 open to participants now, 11 under way, 5 of them phase 3. Obesity · Huadong Medicine Co., Ltd..

Planned enrollment
8th of 13
180 · median 200
Started
2024
with 2 others
Phase 2
3 of 13
3 open now
Primary completion
2024-10
later than 0 of 10 live
Registered
3rd of 13
by date

Among the 13 studies in Obesity by Huadong Medicine Co., Ltd., this one is the 8th largest by planned enrollment, is one of 3 that started in 2024, is one of 3 in phase 2, reaches primary completion later than 0 of the 10 other live ones, and was the 3rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

10 of the 13 studies in Obesity by Huadong Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Obesity by Huadong Medicine Co., Ltd., or all of them as a file.
02

Study summary

It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults.

Read the detailed description

This multicenter, randomized, double-blind, placebo-controlled phase II clinical trial aims to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults. Participants with a BMI between 24 and 40 will be include. A total of 180 participants will be randomized in a 1:1:1:1 ratio to receive different doses of HDM1002 or placebo. Following the screening period to confirm eligibility up to 2-weeks, the study will consist of a treatment period will be 12 weeks, followed by an approximate 4-week follow-up.

03

Conditions studied

  • Overweight and Obesity

Browse trials for

Keywords

  • HDM1002 tablet
  • overweight and obesity
  • Glucagon-Like Peptide-1 Receptor Agonists
04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 180 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is the lead sponsor of 50 studies on the registry; 38 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between 18 and 65 years of age (inclusive).
  • ≥28 but \< 40.0 kg/m2 at screening or randomization,or BMI≥24.0 kg/m2 but \< 28 kg/m2 with any of the following:

    1. Hypertension
    2. Impaired fasting glucose or impaired glucose tolerance
    3. Dyslipidemia
    4. Obstructive sleep apnea syndrome
  • At least one previous failure to lose weight through lifestyle modification was defined as \< 5% weight loss after ≥3 months of lifestyle modification.

Exclusion criteria

Exclusion Criteria:

  • Weight change ≥5% as reported or documented. Previous diagnosis of type 1, type 2, or any other type of diabetes.
  • Diagnosis of overweight or obesity due to other diseases or medications.
  • History or family history of medullary thyroid carcinoma, C cell hyperplasia, or multiple endocrine neoplasia type 2.
  • Have diseases or conditions that affect gastric emptying or gastrointestinal absorption of nutrients, such as bariatric surgery or other gastrectomy, irritable bowel syndrome, dyspepsia, chronic pancreatitis, etc. Or a history of acute pancreatitis or acute gallbladder disease within 3 months before signing ICF.
  • GLP-1R agonist use within 6 months prior to signing ICF.
  • Use of hypoglycemic drugs within 3 months before signing ICF.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    HDM1002 100mg BID

    HDM1002 tablets 100mg twice daily, 12weeks

    Drug: HDM1002 100 mg QD

  • Experimental
    HDM1002 200mg BID

    HDM1002 tablets 200mg twice daily, 12weeks

    Drug: HDM1002 200 mg QD 12weeks

  • Experimental
    HDM1002 400mg QD

    HDM1002 tablets 400mg once daily, 12weeks

    Drug: HDM1002 400 mg QD 12weeks

  • Placebo comparator
    placebo

    Matching placebo will be provided, 12weeks

    Drug: Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Body Weight at Week 12

    Weight was recorded in kilograms (kg), and accuracy to the nearest 0.1 kg.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Percentage Change From Baseline in Body Weight at Week 2, Week 4, Week 6, Week 8, Week 10

    Weight was recorded in kilograms (kg), and accuracy to the nearest 0.1 kg.

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 10

  2. Percentage Change of Participants Achieving Weight Loss ≥ 5% and ≥ 10% at Week 12

    Weight was recorded in kilograms (kg), and accuracy to the nearest 0.1 kg.

    Time frame: Baseline, Week 12

  3. Change From Baseline in Body Mass Index (BMI), And Waist Circumference

    BMI was recorded in kg/m2, and Waist Circumference was recorded in cm

    Time frame: Baseline, Week 12

  4. Percentage change from baseline in fasting lipid profile (total cholesterol, low density lipoprotein [LDL] cholesterol, high density lipoprotein [HDL] cholesterol, non HDL cholesterol, lipoprotein (a) (Lp[a]), triglycerides)

    Fasting Lipid Profiles were measured at planned time points.

    Time frame: Baseline, Week 12

  5. Change From Baseline in Systolic and Diastolic Blood Pressure

    Blood Pressure was measured using an automated device

    Time frame: Baseline, Week 12

  6. Number of Participants with Clinical Laboratory Abnormalities, and Abnormalities in Vital Signs, Physical Examination and Electrocardiogram and Number of Participants With Treatment Emergent Adverse Events

    Vital signs (blood pressure, pulse rate, body temperature, respiratory rate), physical examination, ECG and clinical laboratory evaluations (hematology, clinical chemistry, coagulation, urinalysis, calcitonin, serum amylase and lipase)

    Time frame: Through Week 16]

Other outcomes

  1. Change From Baseline in Fasting Insulin

    The fasting plasma glucose measures the levels of Fasting Insulin were measured at planned time points

    Time frame: Time Frame: Baseline, Week 12

  2. Change From Baseline in Fasting plasma Glucose

    The fasting plasma glucose measures the levels of glucose in the bloodFasting Insulin were measured at planned time points

    Time frame: Time Frame: Baseline, Week 12

  3. Change From Baseline in Fasting C-Peptide,

    The fasting plasma glucose measures the levels of C-Peptide were measured at planned time points

    Time frame: Time Frame: Baseline, Week 12

  4. Change From Baseline in HbA1c at Week 12

    HbA1c can be used as a diagnostic test for diabetes and is a widely recognized objective measure of glycemic control

    Time frame: Time Frame: Baseline, Week 12

  5. Pharmacokinetic (PK) Profiles of HDM1002 and Its Metabolites (If Feasible)

    Area under the curve from time 0 to 24 h(AUC0-24h)

    Time frame: Day 1, Day 15, Day 29, Day 57 and Day 85

  6. Pharmacokinetic (PK) Profiles of HDM1002 and Its Metabolites (If Feasible)

    Maximum plasma concentration (Cmax),

    Time frame: Day 1, Day 15, Day 29, Day 57 and Day 85

  7. Pharmacokinetic (PK) Profiles of HDM1002 and Its Metabolites (If Feasible)

    Minumum plasma concentration (Cmin)

    Time frame: Day 1, Day 15, Day 29, Day 57 and Day 85

  8. Pharmacokinetic (PK) Profiles of HDM1002 and Its Metabolites (If Feasible)

    Time to maximum plasma concentration (Tmax)

    Time frame: Day 1, Day 15, Day 29, Day 57 and Day 85

  9. Pharmacokinetic (PK) Profiles of HDM1002 and Its Metabolites (If Feasible)

    AUCtau

    Time frame: Day 1, Day 15, Day 29, Day 57 and Day 85

08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2024; primary completion for Oct 2024, 3 months later.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 3 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jul 15, 2024
StartEst.
Jul 15, 2024
Primary completionEst.
Oct 30, 2024
CompletionEst.
Nov 30, 2024
Last update
Jul 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06500299
Responsible party
Sponsor
First posted
Jul 15, 2024
Start date
Jul 15, 2024 (estimated)
Primary completion
Oct 30, 2024 (estimated)
Completion
Nov 30, 2024 (estimated)
Last update
Jul 15, 2024

Study contacts

Wenwen Tu
Contact
tuwenwen@eastchinapharm.com
+86-0571-89903388
Xiaoying Li
principal investigator · Zhongshan Hospital, Shanghai, China

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HDM1002

Start the discussion